{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T18:50:21Z","timestamp":1717959021809},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1097\/coc.0b013e31816a6221","type":"journal-article","created":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T07:10:36Z","timestamp":1222845036000},"page":"476-480","source":"Crossref","is-referenced-by-count":12,"title":["A Phase I Study of Oral Topotecan and Pegylated Liposomal Doxorubicin (Doxil) in Platinum-Resistant Ovarian and Peritoneal Cancer"],"prefix":"10.1097","volume":"31","author":[{"given":"Peter G.","family":"Rose","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Smrekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pam","family":"Haba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-12-20210128","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","article-title":"Cancer statistics, 2006.","volume":"56","author":"Jemal","year":"2006","journal-title":"CA Cancer J Clin"},{"key":"R2-12-20210128","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/jcb.240590926","article-title":"Prospective on ovarian cancer: why prevent?","volume":"23","author":"Hoskins","year":"1995","journal-title":"J Cell Biochem Suppl"},{"key":"R3-12-20210128","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1056\/NEJM199311183292108","article-title":"Cancer of the ovary.","volume":"329","author":"Cannistra","year":"1993","journal-title":"N Engl J Med"},{"key":"R4-12-20210128","first-page":"323","article-title":"Medical therapy of advanced malignant epithelial tumours of the ovary.","volume":"10","author":"Colombo","year":"2000","journal-title":"Forum (Genova)"},{"key":"R5-12-20210128","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.","volume":"92","author":"Piccart","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"suppl 5","key":"R6-12-20210128","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.7-suppl_5-20","article-title":"Relapsed ovarian cancer: challenges and management strategies for a chronic disease.","volume":"7","author":"Armstrong","year":"2002","journal-title":"Oncologist"},{"key":"R7-12-20210128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/107327480100806S03","article-title":"Nursing perspectives on patient management during chronic therapy for relapsed ovarian cancer.","volume":"8","author":"Frazier","year":"2001","journal-title":"Cancer Control"},{"key":"R8-12-20210128","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.1992.10.4.513","article-title":"Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.","volume":"10","author":"Markman","year":"1992","journal-title":"J Clin Oncol"},{"key":"R9-12-20210128","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"R10-12-20210128","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.2000.18.5.1062","article-title":"Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group Study.","volume":"18","author":"McGuire","year":"2000","journal-title":"J Clin Oncol"},{"key":"R11-12-20210128","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00000421-200006000-00019","article-title":"A phase I study of liposomal doxorubicin (Doxil) with topotecan.","volume":"23","author":"Ryan","year":"2000","journal-title":"Am J Clin Oncol"},{"key":"R12-12-20210128","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003088-199631020-00001","article-title":"Clinical pharmacokinetics of topotecan.","volume":"31","author":"Herben","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"R13-12-20210128","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","article-title":"A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin.","volume":"57","author":"Gewirtz","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"R14-12-20210128","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/0959-8049(92)90107-D","article-title":"Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells.","volume":"28A","author":"Bertrand","year":"1992","journal-title":"Eur J Cancer"},{"key":"R15-12-20210128","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s002280050505","article-title":"Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients.","volume":"54","author":"Jonsson","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"R16-12-20210128","first-page":"691","article-title":"A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.","volume":"8","author":"Seiden","year":"2002","journal-title":"Clin Cancer Res"},{"key":"R17-12-20210128","first-page":"891","article-title":"Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes.","volume":"52","author":"Gabizon","year":"1992","journal-title":"Cancer Res"},{"key":"R18-12-20210128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0959-8049(01)00188-5","article-title":"A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer.","volume":"38","author":"Gore","year":"2002","journal-title":"Eur J Cancer"},{"key":"R19-12-20210128","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1200\/JCO.2001.19.19.3967","article-title":"Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer.","volume":"19","author":"Clarke-Pearson","year":"2001","journal-title":"J Clin Oncol"},{"key":"R20-12-20210128","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.1996.14.5.1545","article-title":"Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.","volume":"14","author":"Rustin","year":"1996","journal-title":"J Clin Oncol"},{"key":"R21-12-20210128","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.ygyno.2004.02.028","article-title":"Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with mullerian malignancies.","volume":"93","author":"Penson","year":"2004","journal-title":"Gynecol Oncol"},{"key":"R22-12-20210128","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/07357900500359877","article-title":"Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.","volume":"23","author":"Garcia","year":"2005","journal-title":"Cancer Invest"},{"issue":"suppl 5","key":"R23-12-20210128","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1634\/theoncologist.7-suppl_5-29","article-title":"Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer.","volume":"7","author":"Morris","year":"2002","journal-title":"Oncologist"},{"key":"R24-12-20210128","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1158\/1078-0432.CCR-04-1240","article-title":"Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.","volume":"11","author":"Mirchandani","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R25-12-20210128","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1525-1438.2006.00298.x","article-title":"Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer.","volume":"16","author":"Verhaar-Langereis","year":"2006","journal-title":"Int J Gynecol Cancer"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00000421-200810000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T05:50:38Z","timestamp":1618033838000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-200810000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e31816a6221","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}